23.3 USD
+0.13 (+0.56%)
Last: Feb 3, 2026, 01:05 PM
AAPG gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. Both the profitability and financial health of AAPG have multiple concerns. AAPG is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- AAPG had negative earnings in the past year.
- In the past year AAPG has reported a negative cash flow from operations.
- AAPG had negative earnings in each of the past 5 years.
- In the past 5 years AAPG always reported negative operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of -38.05%, AAPG is in the better half of the industry, outperforming 60.50% of the companies in the same industry.
- AAPG's Return On Equity of -174.06% is on the low side compared to the rest of the industry. AAPG is outperformed by 66.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.05% | ||
| ROE | -174.06% | ||
| ROIC | N/A |
ROA(3y)-27.9%
ROA(5y)-29.89%
ROE(3y)-633.86%
ROE(5y)-409%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- AAPG has a better Gross Margin (90.87%) than 92.75% of its industry peers.
- AAPG's Gross Margin has improved in the last couple of years.
- The Profit Margin and Operating Margin are not available for AAPG so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 90.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y2.55%
2. Health
2.1 Basic Checks
- AAPG does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for AAPG has been increased compared to 1 year ago.
- Compared to 5 years ago, AAPG has more shares outstanding
- Compared to 1 year ago, AAPG has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -0.19, we must say that AAPG is in the distress zone and has some risk of bankruptcy.
- The Altman-Z score of AAPG (-0.19) is comparable to the rest of the industry.
- AAPG has a Debt/Equity ratio of 1.99. This is a high value indicating a heavy dependency on external financing.
- The Debt to Equity ratio of AAPG (1.99) is worse than 78.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.99 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.19 |
ROIC/WACCN/A
WACC6.87%
2.3 Liquidity
- AAPG has a Current Ratio of 1.54. This is a normal value and indicates that AAPG is financially healthy and should not expect problems in meeting its short term obligations.
- With a Current ratio value of 1.54, AAPG is not doing good in the industry: 79.96% of the companies in the same industry are doing better.
- AAPG has a Quick Ratio of 1.53. This is a normal value and indicates that AAPG is financially healthy and should not expect problems in meeting its short term obligations.
- AAPG has a worse Quick ratio (1.53) than 79.20% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.53 |
3. Growth
3.1 Past
- AAPG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -184.96%.
- AAPG shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -56.75%.
- Measured over the past years, AAPG shows a very strong growth in Revenue. The Revenue has been growing by 132.25% on average per year.
EPS 1Y (TTM)-184.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-409.56%
Revenue 1Y (TTM)-56.75%
Revenue growth 3Y227.53%
Revenue growth 5Y132.25%
Sales Q2Q%-71.63%
3.2 Future
- AAPG is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -39.35% yearly.
- Based on estimates for the next years, AAPG will show a very strong growth in Revenue. The Revenue will grow by 22.43% on average per year.
EPS Next Y-185.96%
EPS Next 2Y104%
EPS Next 3Y9.42%
EPS Next 5Y-39.35%
Revenue Next Year-42.1%
Revenue Next 2Y64.73%
Revenue Next 3Y21.64%
Revenue Next 5Y22.43%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- AAPG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Based on the Price/Forward Earnings ratio of 18.56, the valuation of AAPG can be described as rather expensive.
- AAPG's Price/Forward Earnings ratio is rather cheap when compared to the industry. AAPG is cheaper than 94.47% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 25.64, AAPG is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 18.56 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y104%
EPS Next 3Y9.42%
5. Dividend
5.1 Amount
- No dividends for AAPG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:AAPG (2/3/2026, 1:05:04 PM)
23.3
+0.13 (+0.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/bmo
Earnings (Next)N/A N/A
Inst Owners11.12%
Inst Owner Change-25.95%
Ins Owners12.72%
Ins Owner ChangeN/A
Market Cap2.17B
Revenue(TTM)390.60M
Net Income(TTM)-1.16B
Analysts86.15
Price Target35.58 (52.7%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-9.02%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 18.56 | ||
| P/S | 38.5 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 22.58 | ||
| P/tB | 26.37 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.88
EYN/A
EPS(NY)1.26
Fwd EY5.39%
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.61
BVpS1.03
TBVpS0.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.05% | ||
| ROE | -174.06% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 90.87% | ||
| FCFM | N/A |
ROA(3y)-27.9%
ROA(5y)-29.89%
ROE(3y)-633.86%
ROE(5y)-409%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y2.55%
F-Score2
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.99 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 29.84% | ||
| Cap/Sales | 7.12% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.53 | ||
| Altman-Z | -0.19 |
F-Score2
WACC6.87%
ROIC/WACCN/A
Cap/Depr(3y)161.69%
Cap/Depr(5y)588.72%
Cap/Sales(3y)47.03%
Cap/Sales(5y)745.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-184.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-409.56%
EPS Next Y-185.96%
EPS Next 2Y104%
EPS Next 3Y9.42%
EPS Next 5Y-39.35%
Revenue 1Y (TTM)-56.75%
Revenue growth 3Y227.53%
Revenue growth 5Y132.25%
Sales Q2Q%-71.63%
Revenue Next Year-42.1%
Revenue Next 2Y64.73%
Revenue Next 3Y21.64%
Revenue Next 5Y22.43%
EBIT growth 1Y-249.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-258.42%
EBIT Next 3Y-28.37%
EBIT Next 5YN/A
FCF growth 1Y73.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.48%
OCF growth 3YN/A
OCF growth 5YN/A
ASCENTAGE PHARMA GR-ADR / AAPG FAQ
What is the fundamental rating for AAPG stock?
ChartMill assigns a fundamental rating of 2 / 10 to AAPG.
What is the valuation status of ASCENTAGE PHARMA GR-ADR (AAPG) stock?
ChartMill assigns a valuation rating of 1 / 10 to ASCENTAGE PHARMA GR-ADR (AAPG). This can be considered as Overvalued.
Can you provide the profitability details for ASCENTAGE PHARMA GR-ADR?
ASCENTAGE PHARMA GR-ADR (AAPG) has a profitability rating of 2 / 10.
How financially healthy is ASCENTAGE PHARMA GR-ADR?
The financial health rating of ASCENTAGE PHARMA GR-ADR (AAPG) is 2 / 10.